MIAMI — A drug that for years has been approved to treat moderate to severe Alzheimer's disease may have a role in improving the cognitive deficits associated with bipolar disorder. In a randomized, ...

An analysis of studies involving the drug memantine finds a lack of evidence for benefit when the drug is used to treat patients with mild Alzheimer disease and mild cognitive impairment, according to ...

This release is available in German. There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in ...

Progressive cognitive deficits are common in patients with fragile X-associated tremor/ataxia syndrome (FXTAS), with no targeted treatment yet established. In this substudy of the first randomized ...

Memantine might lessen deterioration and improve behavioural symptoms in patients with a neurodegenerative disease known as dementia with Lewy bodies (DLB)*, and has the potential to become a ...

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine, according to a new report. There is no scientific proof that ...

Older adults taking memantine for Alzheimer’s disease may face a higher risk of irregular heartbeats, according to a growing body of evidence drawn from electronic health records and adverse-event ...

The methods used in this study were approved by the UCSD Human Subject Institutional Review Board (human studies) or were in accordance with the National Institute of Health Guide for the Care and Use ...

Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the ...

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute ...